Anti-oxidative effect of the β-blocker carvedilol on diabetic nephropathy in non-obese type 2 diabetic rats

Clinical and Experimental Pharmacology and Physiology

Volumn 42, Issue 9, 2015, Pages 972-978

  Yonekura, Yuriko ^a   Fujii, Hideki ^a   Nakai, Kentaro ^a   Kono, Keiji ^a   Goto, Shunsuke ^a   Shinohara, Masami ^b   Nishi, Shinichi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CLEA Japan Inc   (Japan)

Author keywords

Carvedilol; Diabetic nephropathy; Oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; CARVEDILOL; GLYCOPROTEIN GP22 PHOX; GLYCOPROTEIN GP47 PHOX; HEMOGLOBIN A1C; INSULIN; MESSENGER RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DISEASE COURSE; GLOMERULAR VOLUME; GLOMERULUS; HEART RATE; KIDNEY MASS; MALE; MESANGIAL INDEX; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; RENAL SYSTEM PARAMETERS; SPONTANEOUSLY DIABETIC TORII RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINARY ALBUMIN EXCRETION; URINARY EXCRETION;

EID: 84940376587     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12447     Document Type: Article

References (41)

1. Gnudi L. Cellular and molecular mechanisms of diabetic glomerulopathy. Nephrol. Dial. Transplant. 2012; 27: 2642-9.
2. Tavafi M. Diabetic nephropathy and antioxidants. J. Nephropathology 2013; 2: 20-7.
3. Nascimento Gomes GN, Barbosa FT, Radaeli RF, Cavanal MF, Aires MM, Zaladek Gil F. Effect of D-α-tocopherol on tubular nephron acidification by rats with induced diabetes mellitus. Braz. J. Med. Biol. Res. 2005; 38: 1043-51.
4. Kim SS, Gallaher DD, Csallany AS. Vitamin E and probucol reduce urinary lipophilic aldehydes and renal enlargement in streptozotocin-induced diabetic rats. Lipids 2000; 35: 1225-37.
5. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2012; 2(Suppl.): 337-414.
6. Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int. 2006; 70: 1905-13.
7. Dandona P, Ghanim H, Brooks DP. Antioxidant activity of carvedilol in cardiovascular disease. J. Hypertens. 2007; 25: 731-41.
8. Dandona P, Karne R, Ghanim H, Hamouda W, Aljada A, Magsino CH Jr. Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation 2000; 101: 122-4.
9. Spallarossa P, Garibaldi S, Altieri P et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J. Mol. Cell. Cardiol. 2004; 37: 837-46.
10. Fujii H, Kono K, Nakai K et al. Oxidative and nitrosative stress and progression of diabetic nephropathy in type 2 diabetes. Am. J. Nephrol. 2010; 31: 342-52.
11. Wang R, Miura T, Harada N et al. Pleiotropic effects of the beta-adrenoceptor blocker carvedilol on calcium regulation during oxidative stress-induced apoptosis in cardiomyocytes. J. Pharmacol. Exp. Ther. 2006; 318: 45-52.
12. Goto S, Fujii H, Kono K et al. Carvedilol ameliorates low-turnover bone disease in non-obese type 2 diabetes. Am. J. Nephrol. 2011; 34: 281-90.
13. Shinohara M, Masuyama T, Shoda T et al. A new spontaneously diabetic non-obese Torii rat strain with severe ocular complications. Int. J. Exp. Diabetes Res. 2000; 1: 89-100.
14. Morgensen CE. Microalbuminuria, blood pressure and diabetic renal disease: Origin and development of ideas. Diabetologia 1999; 42: 263-85.
15. Rudberg S, Persson B, Dahlquist G. Increased glomerular filtration rate as a predictor of diabetic nephropathy: An 8-year prospective study. Kidney Int. 1992; 41: 822-8.
16. Dachs S, Churg J, Mautner W, Grishman E. Diabetic nephropathy. Am. J. Pathol. 1964; 44: 155-68.
17. Wolf G, Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int. 1999; 56: 393-405.
18. Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-6.
19. Karalliedde J, Viberti G. Microalbuminuria and cardiovascular risk. Am. J. Hypertens. 2004; 17: 986-93.
20. Arnlov J, Evans JC, Meigs JB et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: Framingham Heart Study. Circulation 2005; 112: 969-75.
21. Hillege HL, Fidler V, Diercks GFH et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-82.
22. Singh A, Friden V, Dasgupta I et al. High glucose causes dysfunction of the human glomerular endothelial glycocalyx. Am. J. Physiol. Renal. Physiol. 2011; 300: F40-8.
23. Singh A, Ramnath RD, Foster RR et al. Reactive oxygen species modulate the barrier function of the human glomerular endothelial glycocalyx. PLoS ONE 2013; 8: e55852.
24. Kinugasa S, Tojo A, Sakai T et al. Selective albuminuria via podocyte albumin transport in puromycin nephrotic rats is attenuated by an inhibitor of NADPH oxidase. Kidney Int. 2011; 80: 1328-38.
25. Sedeek M, Nasrallah R, Touyz RH, Hebert RL. NADPH oxidase, reactive oxygen species, and the kidney: Friend and foe. J. Am. Soc. Nephrol. 2013; 24: 1512-8.
26. Sharma K, Cook A, Smith M, Valancius C, Inscho EW. TGF-beta impairs renal autoregulation via generation of ROS. Am. J. Physiol. Renal. Physiol. 2005; 288: F1069-77.
27. Kobori H, Nishiyama A, Harrison-Bernard LM, Navar LG. Urinary angiotensinogen as an indicator of intrarenal angiotensin status in hypertension. Hypertension 2003; 41: 42-9.
28. Nakamura K, Kusano K, Nakamura Y et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002; 105: 2867-71.
29. Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 2001; 344: 1651-8.
30. DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH. Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nevibolol). Am. J. Cardiol. 2013; 111: 765-9.
31. Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomized controlled trial. Lancet 2003; 362: 7-13.
32. Tadolini B, Franconi F. Carvedilol inhibition of lipid peroxidation: A new antioxidative mechanism. Free Radic. Res. 1998; 29: 377-87.
33. Kawai K, Qin F, Shite J, Mao W, Fukuoka S, Liang CS. Importance of antioxidant and antiapoptotic effects of beta-receptor blockers in heart failure therapy. Am. J. Physiol. Heart Circ. Physiol. 2004; 287: H1003-12.
34. Abdel-Raheem MH, Salim SU, Mosad E, Al-Rifaay A, Salama HS, Hasan-Ali H. Antiapoptotic and antioxidant effects of carvedilol and vitamin E protect against diabetic nephropathy and cardiomyopathy in diabetic Wistar albino rats. Horm. Metab. Res. 2015; 47: 97-106.
35. Morsy MA, Ibrahim SA, Amin EF, Kamel MY, Abdelwahab SA, Hassan MK. Carvedilol ameliorates early diabetic nephropathy in streptozotocin-induced diabetic rats. Biomed. Res. Int. 2014; 2014: 105214.
36. Rodrigues MA, Rodrigues JL, Martins NM et al. Carvedilol protects against cisplatin-induced oxidative stress, redox state unbalance and apoptosis in rat kidney mitochondria. Chem. Biol. Interact. 2011; 189: 45-51.
37. Hayashi T, De Velasco MA, Saito Y et al. Carvedilol protects tubular epithelial cells from ischemia-reperfusion injury by inhibiting oxidative stress. Int. J. Urol. 2010; 17: 989-95.
38. Arozal W, Watanabe K, Veeraveedu PT et al. Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats. Toxicology 2010; 274: 18-26.
39. Huang H, Shan J, Pan XH, Wang HP, Qian LB, Xia Q. Carvedilol improved diabetic rat cardiac function depending on antioxidant ability. Diabetes Res. Clin. Pract. 2007; 75: 7-13.
40. Okamoto H, Hori M, Matsuzaki M et al. Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol: Japanese chronic heart failure (J-CHF) study. Int. J. Cardiol. 2013; 164: 238-44.
41. Ichinose K, Maeshima Y, Yamamoto Y et al. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes 2005; 54: 2891-903.